Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupivacaine + ibuprofen is a combination of two drugs used for multimodal analgesia, particularly in the perioperative and postoperative setting. Bupivacaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting nerve impulse transmission and providing local or regional anesthesia. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing the synthesis of prostaglandins involved in pain, inflammation, and fever. The combination aims to provide synergistic pain relief by targeting different mechanisms—local nerve blockade from bupivacaine and systemic anti-inflammatory effects from ibuprofen—thereby reducing opioid requirements after surgery[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + ibuprofen.